Editor’s Note: LimeLight is a new feature in WRAL TechWire providing another way to publish great news. Be sure to check out other LimeLight-worthy news at this link.
DURHAM – Brii Biosciences Limit (“Brii Bio“or the” Company “, stock code: 2137.HK), a multinational company developing innovative therapies for diseases with significant unmet medical needs and significant public health burdens, the appointment of Coy stout as Senior Vice President and Head of US Market Access and Patient Advocacy.
Mr. Stout brings with him over 25 years of experience as a leader in the public health and biopharmaceutical industry, establishing strategic business planning and infrastructure to help advance patient access in the United States. to important drugs in a variety of disease areas, particularly infectious diseases. .
âAs our team progresses rapidly to advance regulatory cases in the United States for BRII-196 / BRII-198, a combination of monoclonal antibodies for the treatment of COVID-19, Coy will be an indispensable member of our leadership team. as we prepare for our next stage of growth, âsaid Zhi hong, Ph.D., CEO of Brii Bio. “Coy’s deep expertise in market access and reimbursement strategy for several infectious disease products, and in addition, his passion for public health and patient care, will allow us to build a business platform. success in delivering our COVID-19 antibody therapy to more patients in critical situations. need.
Before joining Brii BioMr. Stout was Vice President of Commercial Access and Reimbursement in the United States, overseeing major federal accounts at Gilead Sciences. He has held increasing leadership roles at Gilead over his 17-year tenure, including roles focused on commercial access and reimbursement and working closely with government affairs and policy teams. to inform product planning initiatives. In addition to his expertise in drug coverage, innovative payment models and patient support programs, Mr. Stout has a proven track record as a leader in access and reimbursement efforts for more than 30 product launches. . As a longtime patient care advocate, he also has experience in supervising community-based teams as a licensed social worker dedicated to supporting people living with HIV / AIDS.
“I can’t wait to join Brii Bio during this exciting time of growth and by tapping into my deep understanding of the industry, as well as my passion for health equity, to ultimately build a robust commercialization program for BRII-196 / BRII-198 and future products in the company’s pipeline, âsaid Coy stout, Senior Vice President and Head of US Market Access and Patient Advocacy at Brii Bio.
For more information on Brii Bio and its management team, visit the website at www.BriiBio.com.